As a blockchain strategist, I’ve seen wild swings—but this? A struggling eye drug company buying $50M in HYPE tokens to survive? This isn’t speculation. It’s a full-blown financial metamorphosis. From near-death to DeFi revival, Eyenovia proves that in crypto’s new era, even legacy firms can reinvent their balance sheets on-chain. Let’s break down how $HYPE became the ultimate corporate lifeline—and why HyperStrategy might be the next frontier for institutional capital.